Recent Investment Analysts’ Ratings Changes for Travere Therapeutics (TVTX)

A number of research firms have changed their ratings and price targets for Travere Therapeutics (NASDAQ: TVTX):

• 9/13/2024 – Travere Therapeutics had its price target raised by analysts at JPMorgan Chase & Co. from $20.00 to $23.00. They now have an “overweight” rating on the stock.
• 9/10/2024 – Travere Therapeutics had its price target raised by analysts at Canaccord Genuity Group Inc. from $18.00 to $23.00. They now have a “buy” rating on the stock.
• 9/9/2024 – Travere Therapeutics was upgraded by analysts at Guggenheim from a “neutral” rating to a “buy” rating. They now have a $25.00 price target on the stock.
• 9/6/2024 – Travere Therapeutics had its price target raised by analysts at Citigroup Inc. from $14.00 to $23.00. They now have a “buy” rating on the stock.
• 9/6/2024 – Travere Therapeutics had its price target raised by analysts at Bank of America Co. from $18.00 to $19.00. They now have a “buy” rating on the stock.
• 9/6/2024 – Travere Therapeutics had its price target raised by analysts at HC Wainwright from $20.00 to $23.00. They now have a “buy” rating on the stock.
• 8/13/2024 – Travere Therapeutics had its price target raised by analysts at JPMorgan Chase & Co. from $19.00 to $20.00. They now have an “overweight” rating on the stock.
• 8/5/2024 – Travere Therapeutics had its price target raised by analysts at HC Wainwright from $19.00 to $20.00. They now have a “buy” rating on the stock.
• 8/2/2024 – Travere Therapeutics had its price target raised by analysts at Barclays PLC from $12.00 to $14.00. They now have an “overweight” rating on the stock.
• 8/2/2024 – Travere Therapeutics had its price target raised by analysts at Wedbush from $13.00 to $16.00. They now have an “outperform” rating on the stock.
• 8/2/2024 – Travere Therapeutics had its price target raised by analysts at Piper Sandler from $11.00 to $12.00. They now have a “neutral” rating on the stock.

Travere Therapeutics Stock Up 7.2 %

NASDAQ:TVTX traded up $0.97 during mid-day trading on Monday, hitting $14.45. 2,643,110 shares of the company’s stock were exchanged, compared to its average volume of 1,261,429. Travere Therapeutics, Inc. has a one year low of $5.12 and a one year high of $14.72. The business has a fifty day moving average price of $9.68 and a 200 day moving average price of $7.99. The company has a market cap of $1.11 billion, a PE ratio of -6.88 and a beta of 0.71. The company has a debt-to-equity ratio of 24.96, a current ratio of 3.04 and a quick ratio of 2.99.

Travere Therapeutics (NASDAQ:TVTX) last posted its quarterly earnings data on Thursday, August 1st. The company reported ($0.90) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.87) by ($0.03). The company had revenue of $54.12 million for the quarter, compared to the consensus estimate of $49.50 million. Travere Therapeutics had a negative net margin of 82.14% and a negative return on equity of 269.18%. Equities analysts predict that Travere Therapeutics, Inc. will post -3.96 EPS for the current year.

Insider Buying and Selling at Travere Therapeutics

In other news, CEO Eric M. Dube sold 21,125 shares of the business’s stock in a transaction on Monday, September 9th. The stock was sold at an average price of $11.52, for a total value of $243,360.00. Following the completion of the transaction, the chief executive officer now owns 361,975 shares in the company, valued at $4,169,952. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, SVP William E. Rote sold 4,387 shares of Travere Therapeutics stock in a transaction on Monday, September 9th. The stock was sold at an average price of $11.52, for a total value of $50,538.24. Following the completion of the sale, the senior vice president now owns 84,455 shares of the company’s stock, valued at $972,921.60. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Eric M. Dube sold 21,125 shares of the firm’s stock in a transaction dated Monday, September 9th. The stock was sold at an average price of $11.52, for a total value of $243,360.00. Following the completion of the transaction, the chief executive officer now directly owns 361,975 shares in the company, valued at $4,169,952. The disclosure for this sale can be found here. In the last ninety days, insiders sold 30,707 shares of company stock worth $352,712. 3.75% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Travere Therapeutics

Hedge funds have recently modified their holdings of the business. EntryPoint Capital LLC bought a new position in Travere Therapeutics in the 1st quarter worth $32,000. DRW Securities LLC purchased a new stake in Travere Therapeutics in the second quarter worth about $95,000. Forefront Analytics LLC raised its stake in shares of Travere Therapeutics by 10.2% in the second quarter. Forefront Analytics LLC now owns 13,317 shares of the company’s stock worth $109,000 after buying an additional 1,237 shares during the period. Sei Investments Co. purchased a new position in shares of Travere Therapeutics during the 2nd quarter valued at about $117,000. Finally, Quest Partners LLC lifted its position in shares of Travere Therapeutics by 240.6% during the 2nd quarter. Quest Partners LLC now owns 14,336 shares of the company’s stock valued at $118,000 after buying an additional 10,127 shares in the last quarter.

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.